{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:37Z","timestamp":1786986877768,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clon.2017.01.007","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T16:16:27Z","timestamp":1486224987000},"page":"348-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care \u2014 Cancer Care Ontario Clinical Practice Guideline"],"prefix":"10.1016","volume":"29","author":[{"given":"S.M.H.","family":"Alibhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zukotynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Walker-Dilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Emmenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2017.01.007_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1995.13.2.502","article-title":"The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation","volume":"13","author":"Browman","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2017.01.007_bib2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1200\/JCO.1998.16.3.1226","article-title":"Progress of clinical oncology guidelines development using the practice guidelines development cycle: the role of practitioner feedback","volume":"16","author":"Browman","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2017.01.007_bib3","unstructured":"Guideline 3-14v2: Bone health and bone-targeted therapies for prostate cancer. Available at: https:\/\/www.cancercare.on.ca\/common\/pages\/UserFile.aspx?fileId=364328 [Accessed 30 September 2016]."},{"issue":"17","key":"10.1016\/j.clon.2017.01.007_bib4","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1503\/cmaj.100771","article-title":"2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary","volume":"182","author":"Papaioannou","year":"2010","journal-title":"Can Med Assoc J"},{"issue":"Suppl. 3","key":"10.1016\/j.clon.2017.01.007_bib5","first-page":"S1","article-title":"NCCN Task Force Report: bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J\u00a0Natl Compr Cancer Network"},{"issue":"8","key":"10.1016\/j.clon.2017.01.007_bib6","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1249\/MSS.0000000000000265","article-title":"Skeletal response to resistance and impact training in prostate cancer survivors","volume":"46","author":"Winters-Stone","year":"2014","journal-title":"Med Sci Sports Exercise"},{"issue":"10","key":"10.1016\/j.clon.2017.01.007_bib7","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3109\/0284186X.2015.1037008","article-title":"Effects of strength training on body composition, physical functioning and quality of life in prostate cancer patients during androgen deprivation therapy","volume":"54","author":"Nilsen","year":"2015","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.clon.2017.01.007_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bju.12646","article-title":"Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial","volume":"115","author":"Cormie","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.clon.2017.01.007_bib9","first-page":"146","article-title":"Group exercise versus personal training for prostate cancer patients: a pilot randomized trial","volume":"3","author":"Santa Mina","year":"2012","journal-title":"J\u00a0Cancer Ther"},{"key":"10.1016\/j.clon.2017.01.007_bib10","unstructured":"Guideline 19-5: Exercise for people with cancer. Available at: https:\/\/www.cancercare.on.ca\/common\/pages\/UserFile.aspx?fileId=342805 [Accessed 10 August 2016]."},{"issue":"8","key":"10.1016\/j.clon.2017.01.007_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.clon.2017.01.007_bib12","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.7314\/APJCP.2013.14.5.3337","article-title":"Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis","volume":"14","author":"Ding","year":"2013","journal-title":"Asian Pacific J Cancer Prev"},{"issue":"4","key":"10.1016\/j.clon.2017.01.007_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/pcan.2013.35","article-title":"RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients","volume":"16","author":"Kachnic","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clon.2017.01.007_bib14","first-page":"CD004523","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"1","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2017.01.007_bib15","first-page":"CD003376","article-title":"Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"1","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2017.01.007_bib16","first-page":"CD001155","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"1","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.clon.2017.01.007_bib17","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00198-015-3148-4","article-title":"Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials","volume":"26","author":"Chen","year":"2015","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.clon.2017.01.007_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1442-2042.2006.01721.x","article-title":"Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study","volume":"14","author":"Rodrigues","year":"2007","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.clon.2017.01.007_bib19","first-page":"321","article-title":"Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8","volume":"18","author":"Kearns","year":"2010","journal-title":"Support Care Cancer"},{"issue":"27","key":"10.1016\/j.clon.2017.01.007_bib20","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1200\/JCO.2007.15.1233","article-title":"Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy","volume":"26","author":"Greenspan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2017.01.007_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3816\/CGC.2007.n.003","article-title":"The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy","volume":"5","author":"Israeli","year":"2007","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.clon.2017.01.007_bib22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.clon.2017.01.007_bib23","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.24404","article-title":"Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma","volume":"115","author":"Satoh","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clon.2017.01.007_bib24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12032-013-0657-x","article-title":"Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases","volume":"30","author":"Wang","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.clon.2017.01.007_bib25","unstructured":"Summary Minutes of the Oncologic Drugs Advisory Committee Meeting February 8, 2012. Available at: www.fda.gov\/downloads\/Advisorycommittees\/CommitteesMeetingMaterials\/Drugs%20\/OncologicDrugsAdvisoryCommittee\/UCM293709.pdf [Accessed 10 August 2016]."},{"issue":"3","key":"10.1016\/j.clon.2017.01.007_bib26","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.clon.2017.01.007_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer\u2013results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9810","key":"10.1016\/j.clon.2017.01.007_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2017.01.007_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.6028\/jres.120.004","article-title":"Revision of the NIST standard for (223)Ra: new measurements and review of 2008 data","volume":"120","author":"Zimmerman","year":"2015","journal-title":"J\u00a0Res Natl Inst Stand Technol"},{"key":"10.1016\/j.clon.2017.01.007_bib30","unstructured":"Guideline 3-15: Systemic therapy in men with metastatic castration-resistant prostate cancer. Available at: https:\/\/www.cancercare.on.ca\/common\/pages\/UserFile.aspx?fileId=318883 [Accessed 10 August 2016]."},{"issue":"4","key":"10.1016\/j.clon.2017.01.007_bib31","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2010.11.026","article-title":"Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline","volume":"79","author":"Lutz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3\u20134","key":"10.1016\/j.clon.2017.01.007_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5489\/cuaj.2526","article-title":"The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC)","volume":"9","author":"Saad","year":"2015","journal-title":"Can Urol Assoc J"},{"issue":"9768","key":"10.1016\/j.clon.2017.01.007_bib33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clon.2017.01.007_bib34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.clon.2017.01.007_bib35","first-page":"3837","article-title":"Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid\/androgen blockade trial on prostate cancer) study","volume":"33","author":"Ueno","year":"2013","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.clon.2017.01.007_bib36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.clon.2017.01.007_bib37","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A\u00a0double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.clon.2017.01.007_bib38","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A\u00a0randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.clon.2017.01.007_bib39","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2017.01.007_bib40","first-page":"CD006250","article-title":"Bisphosphonates for advanced prostate cancer","volume":"4","author":"Yuen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.clon.2017.01.007_bib41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.clon.2017.01.007_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.clon.2017.01.007_bib43","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clon.2017.01.007_bib44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","article-title":"Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study","volume":"8","author":"Nilsson","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2017.01.007_bib45","first-page":"CD003347","article-title":"Radioisotopes for metastatic bone pain","volume":"7","author":"Roque","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.clon.2017.01.007_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A\u00a0comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.clon.2017.01.007_bib47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group","volume":"44","author":"Oosterhof","year":"2003","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clon.2017.01.007_bib48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpainsymman.2004.07.008","article-title":"Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study","volume":"29","author":"Nilsson","year":"2005","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"12","key":"10.1016\/j.clon.2017.01.007_bib49","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s11255-014-0824-9","article-title":"Docetaxel with or without zoledronic acid for castration-resistant prostate cancer","volume":"46","author":"Pan","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"10.1016\/j.clon.2017.01.007_bib50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2012.07.002","article-title":"Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases","volume":"11","author":"Nilsson","year":"2013","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1016\/j.clon.2017.01.007_bib51","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clon.2017.01.007_bib52","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0959-8049(05)80417-4","article-title":"Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group","volume":"29A","author":"Kylmala","year":"1993","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.clon.2017.01.007_bib53","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2017.01.007_bib54","first-page":"790","article-title":"A\u00a0randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases","volume":"173","author":"Figg","year":"2005","journal-title":"J\u00a0Urol"},{"issue":"16","key":"10.1016\/j.clon.2017.01.007_bib55","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.ejca.2012.05.014","article-title":"Randomised phase II\/III study of docetaxel with or without risedronate in patients with metastatic castration resistant prostate cancer (CRPC), the Netherlands Prostate Study (NePro)","volume":"48","author":"Meulenbeld","year":"2012","journal-title":"Eur J Cancer"},{"issue":"10024","key":"10.1016\/j.clon.2017.01.007_bib56","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"Suppl.","key":"10.1016\/j.clon.2017.01.007_bib57","article-title":"CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer","volume":"33","author":"Himelstein","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665551730033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093665551730033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:43:54Z","timestamp":1760543034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093665551730033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S093665551730033X"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2017.01.007","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care \u2014 Cancer Care Ontario Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2017.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}